Evaxion Biotech A/S (EVAX)
NASDAQ
Healthcare
Biotechnology
$3.61
▼ -4.75%
Market Cap
$22.8M
Sector
Healthcare
Industry
Biotechnology
Beta
0.23
52-Wk Range
2.07-12.15
CEO
Helen Katrina Tayton-Martin
Country
DK
Currency
USD
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing …
Open full interactive analysis & DCF →